Cargando…

Phase I dose-escalation oncology trials with sequential multiple schedules

BACKGROUND: Conventional methods for phase I dose-escalation trials in oncology are based on a single treatment schedule only. More recently, however, multiple schedules are more frequently investigated in the same trial. METHODS: Here, we consider sequential phase I trials, where the trial proceeds...

Descripción completa

Detalles Bibliográficos
Autores principales:	Günhan, Burak Kürsad, Weber, Sebastian, Seroutou, Abdelkader, Friede, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045405/ https://www.ncbi.nlm.nih.gov/pubmed/33853539 http://dx.doi.org/10.1186/s12874-021-01218-9

Ejemplares similares

A design‐by‐treatment interaction model for network meta‐analysis and meta‐regression with integrated nested Laplace approximations
por: Günhan, Burak Kürsad, et al.
Publicado: (2018)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Dose Escalation Methods in Phase I Cancer Clinical Trials
por: Le Tourneau, Christophe, et al.
Publicado: (2009)

Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models
por: Pantoja, Kristyn, et al.
Publicado: (2022)

Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial
por: Micallef, Sandrine, et al.
Publicado: (2022)

Phase I Dose-Escalation Study of Nimustine in Tumor-Bearing Dogs
por: TAKAHASHI, Masashi, et al.
Publicado: (2014)

Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial
por: Barone, C, et al.
Publicado: (2007)

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
por: Marshall, John, et al.
Publicado: (2012)

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
por: Reynolds, Kerry Lynn, et al.
Publicado: (2017)

Escalator: An Autonomous Scheduling Scheme for Convergecast in TSCH
por: Oh, Sukho, et al.
Publicado: (2018)

Phase I dose-escalation trial of intravaginal curcumin in women for cervical dysplasia
por: Gattoc, Leda, et al.
Publicado: (2016)

Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic data
por: Hassing, Gerardus J., et al.
Publicado: (2022)

Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review
por: Zehentmayr, Franz, et al.
Publicado: (2020)

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
por: Le Tourneau, Christophe, et al.
Publicado: (2012)

Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy
por: Chapman, Christopher H, et al.
Publicado: (2018)

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
por: Sakiyama, T, et al.
Publicado: (2015)

Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2015)

Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
por: Cao, Junning, et al.
Publicado: (2017)

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
por: Yao, James C, et al.
Publicado: (2017)

Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
por: Tsai, Hui-Jen, et al.
Publicado: (2021)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations
por: Ursino, Moreno, et al.
Publicado: (2017)

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
por: Brada, M, et al.
Publicado: (1999)

Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034
por: Bissett, D, et al.
Publicado: (2001)

Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs
por: Axiak, Sandra M, et al.
Publicado: (2011)

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
por: Naing, Aung, et al.
Publicado: (2013)

INTRAGO: intraoperative radiotherapy in glioblastoma multiforme – a Phase I/II dose escalation study
por: Giordano, Frank A, et al.
Publicado: (2014)

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
por: Regan, Courtney, et al.
Publicado: (2015)

Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers
por: Zimmermann, Torsten, et al.
Publicado: (2018)

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
por: Sarantopoulos, John, et al.
Publicado: (2017)

Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer
por: Juarez, Tiffany M, et al.
Publicado: (2021)

Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies
por: Hatake, Kiyohiko, et al.
Publicado: (2020)

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
por: Sekiguchi, Naohiro, et al.
Publicado: (2022)

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
por: Nadeem, Omar, et al.
Publicado: (2020)

A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia
por: Kirschbaum, Mark, et al.
Publicado: (2011)

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial
por: De Wolf, Katrien, et al.
Publicado: (2017)

Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials
por: Hirakawa, Akihiro, et al.
Publicado: (2019)

Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer.
por: Ardizzoni, A., et al.
Publicado: (1996)

Escalation strategies for combination therapy Phase I trials
por: Sweeting, Michael J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hrjklk9ftge7noh3chminhcrmv